Stock Analysis

Clene Full Year 2022 Earnings: Beats Expectations

Source: Shutterstock

Clene (NASDAQ:CLNN) Full Year 2022 Results

Key Financial Results

  • Net loss: US$29.9m (loss widened by 207% from FY 2021).
  • US$0.46 loss per share (further deteriorated from US$0.16 loss in FY 2021).
NasdaqCM:CLNN Earnings and Revenue History March 15th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Clene Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 39%. Earnings per share (EPS) also surpassed analyst estimates by 20%.

Looking ahead, revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with Clene (at least 2 which are a bit concerning), and understanding them should be part of your investment process.

What are the risks and opportunities for Clene?

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.

View Full Analysis


  • Trading at 97.4% below our estimate of its fair value

  • Revenue is forecast to grow 57.98% per year


  • Has less than 1 year of cash runway

  • Makes less than USD$1m in revenue ($473K)

  • Does not have a meaningful market cap ($89M)

  • Shareholders have been diluted in the past year

  • Volatile share price over the past 3 months

  • Currently unprofitable and not forecast to become profitable over the next 3 years

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report